The CSL Ltd (ASX: CSL) share price reached a new six-year low of $205.82 yesterday.
Today, the market's largest healthcare share is selling for $207.87, up 0.6%, whilst the S&P/ASX 200 Index (ASX: XJO) is up 0.8%.
CSL has lost 23% of its market value since it released its FY25 report on 19 August.
Clearly, investors are nervous.
But several experts have come to the defence of this long-standing ASX 200 blue-chip share.
Here's why they're positive on CSL shares despite their recent dive.
Image source: Getty Images
Should you buy the dip on CSL shares?
CSL may be a tremendous buy-the-dip opportunity today — if these experts are right…
Sell-off of CSL shares 'an overreaction'
After CSL's FY25 report, Macquarie retained its outperform rating with a 12-month price target of $295.90.
The broker said:
Despite downgrades to earnings, we view [Tuesday's] price movement as an overreaction.
Incorporating more conservative FY26 forecasts compared to guidance, we see the current valuation as undemanding (trading at P/E ~20x with ~10% EPS growth).
According to Macquarie's data, CSL shares are now trading on a forward price-to-earnings (P/E) ratio of 19.1x.
This is not only below the current market average P/E but also 2.3 standard deviations lower than the historical norm for CSL stock.
Long-term outlook intact, says expert
Jabin Hallihan from Family Financial Solutions has a buy rating on CSL shares with a price target of $291.31.
The analyst said (courtesy The Bull):
The company continues to grow plasma volumes and expand its product pipeline.
CSL reported solid revenue growth and maintains a strong balance sheet.
Our 12-month analyst valuation is $291.31 as the long-term outlook remains intact.
Morgans says investors are taking 'a glass half full approach'
Following CSL's report, Morgans has a buy rating on this ASX 200 healthcare stock with a trimmed price target of $293.83.
In a new note, the broker commented:
While investors have taken a glass half full approach, we believe the restructuring augments, not masks the underlying business, with streamlining operations and cost savings supporting double-digit earnings growth over the medium term.
Stock is 'bruised not broken': broker
UBS said the market's reaction to CSL's FY25 report reflected concerns over Behring's disappointing performance and the company's strong focus on cost-cutting.
The broker said this "created an overreaction to a modest compositional change in CSL's 3-year EPS growth".
UBS has a 12-month share price target of $300 on CSL shares.
CSL shares 'a potential buying opportunity'
E&P said it was disappointed with CSL's FY25 report but retained a positive rating with a lowered price target of $294.21.
The broker commented:
The key question is whether Behring's weak 2H25 signals structural pressure or a temporary setback.
Management insists it's the latter, although medium-term Ig growth expectations have effectively eased to mid-to-high single digits (still respectable).
On balance, we see the sell-off as a potential buying opportunity.
